绝经激素治疗与妇科恶性肿瘤风险

doi:10.12280/gjszjk.20230261

摘要/Abstract

摘要：

绝经激素治疗（menopausal hormone therapy，MHT）是缓解绝经综合征的有效治疗方案，目前18.16%围绝经期妇女接受MHT治疗。因妇科恶性肿瘤大多具有激素依赖性，MHT的应用对绝经综合征妇女以及罹患妇科恶性肿瘤合并绝经综合征妇女的安全性及有效性，仍存在争议。对于未患有妇科恶性肿瘤的绝经综合征患者合理选择雌激素治疗方案可能降低卵巢癌发病风险，选择含孕激素的MHT方案可能降低子宫内膜癌、宫颈癌发病风险，合理选择MHT方案对于上皮性卵巢癌、早期子宫内膜癌、宫颈鳞状细胞癌、阴道鳞状细胞癌和外阴鳞状细胞癌等可能并不增加复发风险，并延长生存期。本文通过回顾近年全球颁布的MHT指南以及相关临床研究，旨在合理选择MHT方案降低绝经综合征妇女罹患妇科恶性肿瘤的风险，降低已患妇科恶性肿瘤合并绝经综合征患者的复发风险和提高妇科恶性肿瘤患者生存率。

关键词: 生殖器肿瘤, 女（雌）性, 雌激素替代疗法, 复发, 存活率, 治疗

Abstract:

Menopausal hormone therapy (MHT) is an effective treatment for alleviating menopausal syndrome, and 18.16% of perimenopausal women are receiving MHT treatment at present. Most gynecological malignancies are hormone-dependent, so the safety and efficacy of MHT in women with menopausal syndrome and those women with gynecological malignancies combined with menopausal syndrome are still controversial. For the menopausal syndrome patients without gynecological malignancies, reasonable selection of estrogen therapy may reduce the risk of ovarian cancer, and selection of MHT containing progesterone may reduce the risk of endometrial cancer and cervical cancer. As for epithelial ovarian cancer, early endometrial cancer, cervical squamous cell carcinoma, vaginal squamous cell carcinoma and vulvar squamous cell carcinoma, reasonable selection of MHT regimen may not increase the risk of recurrence, while may prolong the survival. By reviewing the MHT guidelines and the related clinical studies issued globally in recent years, we discuss how to rationally select MHT regimens to reduce the risk of gynecological malignancies in women with menopausal syndrome, how to reduce the recurrence risk of patients with gynecological malignancies combined with menopausal syndrome, and how to improve the survival rate of patients with gynecological malignant tumors.

Key words: Genital neoplasms, female, Estrogen replacement therapy, Recurrence, Survival rate, Therapy

张哲, 张崴. 绝经激素治疗与妇科恶性肿瘤风险[J]. 国际生殖健康/计划生育杂志, 2023, 42(6): 519-523.

ZHANG Zhe, ZHANG Wei. Menopausal Hormone Therapy and the Risk of Gynecological Malignancy[J]. Journal of International Reproductive Health/Family Planning, 2023, 42(6): 519-523.

参考文献 24

[1]	Alsugeir D, Wei L, Adesuyan M, et al. Hormone replacement therapy prescribing in menopausal women in the UK: a descriptive study[J]. BJGP Open, 2022, 6(4): BJGPO.2022.0126. doi: 10.3399/BJGPO.2022.0126.
[2]	Yuk JS, Kim M. Effects of menopausal hormone therapy on the risk of ovarian cancer: Health Insurance Database in South Korea-based cohort study[J]. Menopause, 2023, 30(5):490-496. doi: 10.1097/GME.0000000000002176.
[3]	Simin J, Tamimi RM, Callens S, et al. Menopausal hormone therapy treatment options and ovarian cancer risk: A Swedish prospective population-based matched-cohort study[J]. Int J Cancer, 2020, 147(1):33-44. doi: 10.1002/ijc.32706. pmid: 31584190
[4]	Fournier A, Cairat M, Severi G, et al. Use of menopausal hormone therapy and ovarian cancer risk in a French cohort study[J]. J Natl Cancer Inst, 2023, 115(6):671-679. doi: 10.1093/jnci/djad035.
[5]	Liu Y, Ma L, Yang X, et al. Menopausal Hormone Replacement Therapy and the Risk of Ovarian Cancer: A Meta-Analysis[J]. Front Endocrinol(Lausanne), 2019, 10:801. doi: 10.3389/fendo.2019.00801.
[6]	Lee AW, Wu AH, Wiensch A, et al. Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored[J]. Epidemiology, 2020, 31(3):402-408. doi: 10.1097/EDE.0000000000001175. pmid: 32028322
[7]	Rees M, Angioli R, Coleman RL, et al. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis[J]. Maturitas, 2020, 134:56-61. doi: 10.1016/j.maturitas.2020.01.005. pmid: 32059825
[8]	Eeles RA, Morden JP, Gore M, et al. Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial[J]. J Clin Oncol, 2015, 33(35):4138-4144. doi: 10.1200/JCO.2015.60.9719. pmid: 26417001
[9]	Ji E, Kim K, Lee B, et al. Postoperative Hormone Replacement Therapy and Survival in Women with Ovarian Cancer[J]. Cancers (Basel), 2022, 14(13):3090. doi: 10.3390/cancers14133090.
[10]	Brieger KK, Peterson S, Lee AW, et al. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival[J]. Gynecol Oncol, 2020, 158(3):702-709. doi: 10.1016/j.ygyno.2020.06.481. pmid: 32641237
[11]	Baandrup L, Galanakis M, Hannibal CG, et al. Long-term survival of nonlocalized epithelial ovarian cancer among women using menopausal hormone therapy prior to diagnosis: The extreme study[J]. Int J Cancer, 2022, 151(9):1512-1522. doi: 10.1002/ijc.34171. pmid: 35716136
[12]	Tempfer CB, Hilal Z, Kern P, et al. Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review[J]. Cancers (Basel), 2020, 12(8):2195. doi: 10.3390/cancers12082195.
[13]	Prentice RL, Aragaki AK, Chlebowski RT, et al. Randomized Trial Evaluation of the Benefits and Risks of Menopausal Hormone Therapy Among Women 50-59 Years of Age[J]. Am J Epidemiol, 2021, 190(3):365-375. doi: 10.1093/aje/kwaa210. pmid: 33025002
[14]	Loizzi V, Dellino M, Cerbone M, et al. The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows[J]. Int J Mol Sci, 2023, 24(1):764. doi: 10.3390/ijms 24010764.
[15]	中华医学会妇产科学分会绝经学组. 中国绝经管理与绝经激素治疗指南2023版[J]. 中华妇产科杂志, 2023, 58(1):4-21. doi: 10.3760/cma.j.cn112141-20221118-00706.
[16]	Londero AP, Parisi N, Tassi A, et al. Hormone Replacement Therapy in Endometrial Cancer Survivors: A Meta-Analysis[J]. J Clin Med, 2021, 10(14):3165. doi: 10.3390/jcm10143165.
[17]	Kasius JC, Pijnenborg J, Lindemann K, et al. Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification[J]. Cancers (Basel), 2021, 13(22):5848. doi: 10.3390/cancers13225848.
[18]	Londero AP, Xholli A, Bertozzi S, et al. Quantification of Women Who Could Benefit from Hormone Therapy after Endometrial Cancer Treatment: An Analysis of SEER Data[J]. Curr Oncol, 2022, 29(12):9215-9223. doi: 10.3390/curroncol29120721. pmid: 36547135
[19]	Oaknin A, Bosse TJ, Creutzberg CL, et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2022, 33(9):860-877. doi: 10.1016/j.annonc.2022.05.009. pmid: 35690222
[20]	Abu-Rustum NR, Yashar CM, Bean S, et al. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(6):660-666. doi: 10.6004/jnccn.2020.0027.
[21]	卢义函, 王应海, 张红平. 宫颈鳞癌卵巢切除术后的绝经激素治疗分析[J]. 昆明理工大学学报(自然科学版), 2021, 46(2):96-102. doi: 10.16112/j.cnki.53-1223/n.2021.02.253.
[22]	Lete I, Fiol G, Nieto L, et al. The use of menopausal hormone therapy in women survivors of gynecological cancer: safety report based on systematic reviews and meta-analysis[J]. Eur J Gynaecol Oncol, 2021, 42(5):1058-1067. doi: 10.31083/j.ejgo4205155.
[23]	Richardson A, Watson L, Persic M, et al. Safety of hormone replacement therapy in women with a history of cervical adenocarcinoma[J]. Post Reprod Health, 2021, 27(3):167-173. doi: 10.1177/20533691211028518.
[24]	中国抗癌协会妇科肿瘤专业委员会. 阴道恶性肿瘤诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6):546-560. doi: 10.19401/j.cnki.1007-3639.2021.06.12.